Aegerion Pharmaceuticals (AEGR +8.5%) says the FDA has provided a clear and executable pathway for the company to file a New Drug Application for its lead investigational therapeutic, lomitapide, based upon Phase III clinical trial results in 29 patients with HoFH, with a primary endpoint of LDL-C reduction.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Benzinga.com (Feb 5, 2015)
at Benzinga.com (Jan 15, 2015)
at Benzinga.com (Jan 14, 2015)
at Benzinga.com (Jan 12, 2015)
at Nasdaq.com (Dec 16, 2014)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs